US FDA blesses Pfizer's Lyrica for spinal cord injury pain
This article was originally published in Scrip
Executive Summary
Pfizer has racked up another US approval for Lyrica (pregabalin), one of its top-selling medicines, this time expanding the labeling to include management of neuropathic pain associated with spinal cord inury, which can be severely debilitating and may significantly hinder rehabilitation and the ability to regain function.